Revenue growth trajectory and QTC expansion are positive, but cash burn and widening losses keep the stock binary on ZEVASKYN adoption. Watch for Q2 2026 patient treatment numbers and any ABO-701 IND timeline updates. The EPS beat vs consensus may provide a short-term lift, but sustained commercial execution is needed for a fundamental re-rating.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $5.71entry
- T+1 · 6mo ago −1.93%α −2.70% · $5.60
- T+5 · 6mo ago −10.33%α −9.17% · $5.12
- T+20 · 5mo ago −3.15%α −2.54% · $5.53
- T+60 · 3mo ago +26.80%α +22.36% · $7.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abeona reported Q1 2026 net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025, with three patients treated. Net loss widened to $(17.1)M ($(0.30)/share) from $(12.0)M a year ago, driven by SG&A ramp-up and a $7.0M licensing payment for ABO-701. Cash burn and lack of profitability keep the stock in speculative territory despite commercial progress.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue $8.7M (vs $2.4M Q4 2025, $0 in Q1 2025)
- Net loss $(17.1)M or $(0.30)/share vs $(12.0)M or $(0.24)/share in Q1 2025
- Cash, equivalents & short-term investments $168.3M as of March 31, 2026 (down from $191.4M Dec 31, 2025)
- Three patients treated with ZEVASKYN in Q1 2026; QTC network expanded to six sites
- In-licensed ABO-701 (PSMA-SIR-T) for prostate cancer; IND expected H2 2027
- Ophthalmology programs deprioritized
- EPS $(0.30) vs consensus $(0.39), a 23% beat on a GAAP basis
Financial Impact
Q1 2026 product revenue $8.7M; net loss $(17.1)M; cash burn ~$23M in the quarter
Risk Factors
- Cash burn rate of ~$23M/quarter implies ~7 quarters of runway at current spend
- ZEVASKYN adoption still early, only 3 patients treated in Q1; revenue concentration risk
- ABO-701 is preclinical; IND not expected until H2 2027, no near-term catalyst
- Accumulated deficit of $(759)M with no path to profitability visible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293883 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers